Synta downgraded

Stifel downgrades Synta Pharmaceuticals (SNTA) from Hold to Sell.

Analyst Brian Klein cites delayed data readouts, changes in clinical trial designs, management changes and the need for additional capital as reasons for the change of outlook.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs